Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 11:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 302 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol Injection Clear all
Completed Phase 1 Interventional Results available

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

NCT02335983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
59
States / cities
Bakersfield, California • Burbank, California • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 2 Interventional Results available

Harm Reduction With Pharmacotherapy (HaRP)

NCT01932801
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
XR-NTX, Placebo, HRC
Drug · Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

NCT07269873
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
Drug
Lead sponsor
BioCorRx Pharmaceuticals Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Terminated Phase 1 Interventional

MT2004-30: Tomotherapy for Solid Tumors

NCT00623077
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions
filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 3 Interventional Results available

Patient Experience Study of Deoxycholic Acid Injection

NCT02007434
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
Drug · Other
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Phase 2 Interventional

CPX-351 Plus Enasidenib for Relapsed AML

NCT03825796
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia
Interventions
Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Sacramento, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 1, 2026, 11:22 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Autoimmune Basis for Postural Tachycardia Syndrome

NCT02725060
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Orthostatic Intolerance, Cardiovascular Diseases, Primary Dysautonomias
Interventions
phenylephrine, isoproterenol, 25 micro-Ci of radiation, Posture study with blood samples, 24-hour heart rhythm and blood pressure monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic function tests, Rebreathing test, Assessment of splanchnic capacitance, microneurography
Drug · Radiation · Procedure + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Withdrawn Not applicable Interventional

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Management of Pain in Abdominal Non-pancreatic Malignancies

NCT01166529
View directory record Official record
Conditions
Pain, Cancer
Interventions
EUS-guided Celiac Plexus Neurolysis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Nov 1, 2026, 11:22 AM EST
Terminated Not applicable Interventional Results available

Liposomal Bupivacaine in Implant Based Breast Reconstruction

NCT02659501
View directory record Official record
Conditions
Breast Cancer, Postoperative Pain
Interventions
Liposomal bupivacaine, Bupivacaine with epinephrine, Morphine sulfate, Hydrocodone/acetaminophen, Diazepam
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Not applicable Interventional

Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine With Epinephrine

NCT06471348
View directory record Official record
Conditions
Post Operative Pain, Spinal Fusion
Interventions
Bupivacaine liposome injectable suspension, Bupivacaine Hydrochloride and Epinephrine Injection
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 3 Interventional Results available

Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles

NCT03223298
View directory record Official record
Conditions
Pain, Head, Pain Syndrome, Temporomandibular Disorder, Myofascial Pain Syndrome, Myofascial Pain
Interventions
Botulinum toxin type A, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Phase 2Phase 3 Interventional

Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

NCT06910943
View directory record Official record
Conditions
Choline Deficiency, Liver Injury
Interventions
Choline Chloride for Injection, Placebo
Drug
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Aurora, Colorado • Miami Lakes, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 3 Interventional Results available

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

NCT02412878
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Scottsdale, Arizona • Bethesda, Maryland • Rockville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Nov 1, 2026, 11:22 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Behavior Brain Responses

NCT03964350
View directory record Official record
Conditions
Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
Interventions
Ethanol, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

NCT04572685
View directory record Official record
Conditions
Schizophrenia Patients
Interventions
Paliperidone Palmitate
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Perineural Steroids for Peripheral Nerve Blocks

NCT02462148
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Dexamethasone, Bupivacaine, Epinephrine, Saphenous Peripheral Nerve Block
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1Phase 2 Interventional

Functional Endoscopic Sinus Surgery Study

NCT03970655
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1, Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 4 Interventional Results available

Management of Postoperative Pain After Total Knee Replacement.

NCT01163214
View directory record Official record
Conditions
Postoperative Pain, Knee Replacement Arthroplasty
Interventions
Nerve Block, Periarticular Injection
Drug
Lead sponsor
Mark J. Spangehl, M.D.
Other
Eligibility
18 Years to 79 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional

Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green

NCT01335893
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 1, 2026, 11:22 AM EST
Completed Not applicable Interventional

Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control

NCT02002806
View directory record Official record
Conditions
Pancreas Cancer, Biliary Tract Cancer
Interventions
Alcohol Injection, Placebo Injection
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional Results available

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

NCT01949545
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies, Hepatic Impairment
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Detroit, Michigan • Durham, North Carolina • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Phase 1 Interventional

Long Acting Neuraxial Peri-prostatic Block in Cancer

NCT06703437
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dehydrated alcohol, Lidocaine IV
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Nov 1, 2026, 11:22 AM EST